REITIR: Skráð lækkun hlutafjár, heildarfjöldi hluta og atkvæða
Á aðalfundi Reita fasteignafélags hf. þann 2. apríl sl. var samþykkt tillaga stjórnar félagsins um að lækka hlutafé félagsins um 14.550.000 kr. að nafnvirði. Lækkunin tók til eigin hluta félagsins…
Porch Light Health Acquires Comprehensive Behavioral Health Center to Expand Access to Full-Spectrum Addiction Treatment
DENVER, May 12, 2025 (GLOBE NEWSWIRE) -- Porch Light Health, the largest addiction medicine practice in Colorado, offering outpatient Medications for Addiction Treatment (MAT) at more than 60 treatment locations,…
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development…
Kvika banki hf.: Transaction in relation to a share buy-back programme – buy-back is completed
In weeks 19 and 20 Kvika banki hf. („Kvika“ or „the bank“) purchased 14,902,447 of its own shares at the purchase price ISK 202,578,769. See further details below: DateTimeNo. of…
Kvika banki hf.: Reglubundin tilkynning um kaup á eigin bréfum í samræmi við endurkaupaáætlun
Í vikum 19 og 20 keypti Kvika banki hf. („Kvika“ eða „bankinn“) 14.902.447 eigin hluti að kaupverði 202.578.769 kr. eins og nánar er greint frá hér á eftir: DagsetningTímiKeyptir hlutirViðskiptaverð…
Nightfood Signs LOI to Acquire Hilton Garden Inn in Rancho Mirage, California, Adjacent to Disney’s Cotino Development
TARRYTOWN, N.Y., May 12, 2025 (GLOBE NEWSWIRE) -- via IBN – Nightfood Holdings, Inc. (OTCQB: NGTF) (“Nightfood” and the “Company”), a hospitality automation company pioneering artificial intelligence (AI)-powered robotics and…
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress65% of patients with clinically significant portal hypertension (CSPH) at…
Tim Lamb Group Welcomes Paul Gilroy To Their Team of Directors
Cincinnati, OH, May 12, 2025 (GLOBE NEWSWIRE) -- The Tim Lamb Group is pleased to welcome Paul Gilroy to their team. Gilroy joins the Tim Lamb Group as a Director…
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response Data contribute to growing body of support around the anti-fibrotic activity of EFX in…
Akero Therapeutics annonce la publication de l’essai de phase 2b SYMMETRY dans le New England Journal of Medicine
Les résultats confirment le bénéfice potentiel de l’éfruxifermine (EFX) pour déclencher une amélioration de la fibrose chez les patients atteints de cirrhose compensée (fibrose F4) due à une MASH ;…